Immune Response of Human Propagated gammadelta-T-Cells to Neuroblastoma Recommend the Vdelta1+ Subset for gammadelta-T-cell-based Immunotherapy.
 

Posts


Write a Post
10-04-08 08:48 AM
Anonymous
Immune Response of Human Propagated gammadelta-T-Cells to Neuroblastoma Recommend the Vdelta1+ Subset for gammadelta-T-cell-based Immunotherapy.
Reply
Related Articles

Immune Response of Human Propagated gammadelta-T-Cells to Neuroblastoma Recommend the Vdelta1+ Subset for gammadelta-T-cell-based Immunotherapy.

J Immunother. 2008 Oct 1;

Authors: Schilbach K, Frommer K, Meier S, Handgretinger R, Eyrich M

Human peripheral gammadelta-T-cells are able to induce cytolysis of neuroblastoma (Nb) tumor cells. Besides innate effector functions against infected cells and tumors, gammadelta-T-cells are involved in T-helper 1/T-helper 2 (TH1/TH2) differentiation of alphabeta-T-cells. However, as different gammadelta-T-cell subsets vary considerably in their functional properties, the aim of the present study was to define repertoires of cytokines, chemokines, and angiogenic factors of in vitro expanded Vdelta1 and Vdelta2 T cells in response to Nb. After short-term culture, both subsets released TH1 [interleukin (IL)-2, interferon (IFN)-gamma, IL-12, tumor necrosis factor (TNF)-alpha, TNF-beta)] and TH2 cytokines (IL-4, -5, -6, -10, -13, Vdelta1 also transforming growth factor (TGF)-beta, chemokines (I-309, monocyte chemotactic protein (MCP)-1-3, regulated upon activation, normal T-cell expressed and secreted), ILs (IL-1, -8, -15), cytokines (leptin) as well as angiogenic growth factors [angiogenin (ANG), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), Insulin-like growth factor (IGF)-I]. These molecules were expressed at higher levels in Vdelta2 than Vdelta1 T cells. Nb challenge changed protein expression. TH2 cytokine and IFN-gamma release was blocked in both gammadelta-T-cell subsets. In Vdelta2 gammadelta-T-cells, TH1 cytokines were down-regulated and tumor growth-promoting factors (ANG, VEGF, EGF, and IGF-I) were strongly up-regulated. In contrast, Vdelta1 gammadelta-T-cells stopped the release of tumor-supportive factors and tolerogenic TGF-beta, and strongly up-regulated TNF-alpha, TNF-beta, MCP-1 and -2 and maintained their IL-2 production. In summary, our data show that after being challenged with Nb cells, propagated Vdelta1rather than Vdelta2 T cells support antitumor responses by secretion of proinflammatory cytokines. Furthermore, in contrast to other cell types, Vdelta1 T cells do not sustain a growth-promoting or tolerogenic microenvironment. These data make Vdelta1 T cells an ideal candidate for upcoming immunotherapy trials in Nb.

PMID: 18832998 [PubMed - as supplied by publisher]